Evotec deregisters from the US Securities and Exchange Commission

Tuesday, 04. January 2011 07:50
Evotec AG /
Evotec deregisters from the US Securities and Exchange Commission
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 4 January 2011: Evotec AG (Frankfurt Stock Exchange, TecDAX:
EVT; OTCBB: EVTCY) announced today that on 30 December 2010 it filed a Form 15F
with the Securities and Exchange Commission (SEC) to deregister and terminate
its reporting obligations under the U.S. Securities Exchange Act of 1934
(Exchange Act) for its American Depositary Shares (ADSs) and its ordinary shares
underlying the ADSs. The deregistration and termination of reporting obligations
is expected to take effect in March 2011.

This deregistration from the SEC is the final step following delisting from
NASDAQ, which was initiated in November 2009. Evotec shares of course continue
to be traded on Frankfurt Stock Exchange, Evotec's ADSs are traded on the over-
the-counter (OTC) market in the U.S.

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Tel.:
+49.(0)40.56081-242,  werner.lanthaler@evotec.com

About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule
drugs with operational sites in Europe and Asia. The Company has built
substantial drug discovery expertise and an industrialized platform that can
drive new innovative small molecule compounds into the clinic. In addition,
Evotec has built a deep internal knowledge base in the treatment of diseases
related to neuroscience, pain, oncology, inflammation and metabolic diseases.
Leveraging these skills and expertise the Company intends to develop best-in-
class differentiated therapeutics and deliver superior science-driven discovery
alliances with pharmaceutical and biotechnology companies. Evotec has long-term
discovery alliances with partners including Boehringer Ingelheim, CHDI,
Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates
in clinical development and a series of preclinical compounds and development
partnerships, including for example a strategic alliance with Roche for the EVT
100 compound family, subtype selective NMDA receptor antagonists for use in
treatment-resistant depression and an alliance in the field of diabetes with
Andromeda (Teva). For additional information please go towww.evotec.com.






--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF of Pressrelease:
http://hugin.info/131215/R/1476813/412958.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1476813]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.